Kimia Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2025 ,inter alia, to consider and approve 1. Unaudited Standalone Financial ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.9 pts less than Nifty Microcap 250 and 4.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Kimia Biosciences has called a board meeting on August 14, 2025 to consider and approve its unaudited standalone financial results for the quarter ended June 30, 2025. The board will also review a warning letter dated July 25, 2025 received from BSE Limited, which is a potential red flag for the company. Additionally, the board will consider taking an unsecured loan of ₹2 crore at 8% per annum interest and appoint Mr. Pradip Kumar Sharma as the new Chief Financial Officer. The trading window for insiders is closed until 48 hours after the financial results are declared.
The BSE warning letter is a negative development that investors should monitor closely, as it may signal compliance or disclosure concerns. The new CFO appointment and small loan of ₹2 crore are routine matters, but the warning letter could weigh on the stock in the short term.